Best Shot First: Two ICIs Upfront for Advanced Melanoma

With no biomarkers to say who can safely delay dual therapy, an editorialist said that two checkpoint inhibitors in the first line might be "prudent."

Related Keywords

Melbourne ,Victoria ,Australia ,Italy ,Paolo Antonio Ascierto ,Gary Schwartz ,Bristol Myers Squibb ,Istituto Nazionale Tumori ,Columbia University ,Drug Administration ,University Of Melbourne ,Grant Mcarthur ,Clin Oncol Full ,Melanoma ,Malignant Melanoma ,Skin Cancer ,Alignant Skin Neoplasm ,Biomarker ,Iological Marker ,Immunotherapy ,Single Agent Therapy ,Biologic Therapy ,